Details of the Drug Combination

General Information of Drug Combination (ID: DC6UW4X)

• Drug Combination Name: Ribavirin-TP + LY03004
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  Ribavirin-TP (DM09NGV): Small molecular drug
  LY03004 (DME5TUR): N.A.
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 26.5
  Bliss Independence Score: 26.5
  Loewe Additivity Score: 37.7
  LHighest Single Agent (HSA) Score: 37.7

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Ribavirin-TP

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[2]

Ribavirin-TP Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Hepatitis C virus NS3 helicase (HCV NS3)	TTWXB3E	POLG_HCV1	Inhibitor	[2]

Indication(s) of LY03004

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Phase 3	[3]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] ATP-binding domain of NTPase/helicase as a target for hepatitis C antiviral therapy. Acta Biochim Pol. 2000;47(1):173-80.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)